Abstract
Stability of Ursodiol in SyrSpend SF Cherry Flavored
Author(s): Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
Issue: Nov/Dec 2012 - Volume 16, Number 6
Page(s): 510-512
Note: Electronic version includes errata or revisions.
Abstract
Ursodiol is used in the treatment and prevention of certain types of gallstones and for patients with primary biliary cirrhosis. Ursodiol is marketed for this purpose by Watson Pharma, Inc. as ACTIGALL, by Axcan Scandipharm Inc. as URSO 250 and URSO Forte, and by a number of generic manufacturers. Ursodiol is available as capsules of varying strengths. The need for other dose-form options for those patients who cannot take capsules has led compounding pharmacies to seek other alternatives, namely oral solutions and suspensions. Additionally, some patients are unable to tolerate suspending agents containing alcohol or sorbitol. The objective of this study was to determine the stability of ursodiol in SyrSpend SF Cherry Flavored which does not contain sorbitol or alcohol. The studied sample was compounded into a 30-mcg/mL suspension and stored in a low-actinic plastic bottle at temperatures between 2°C and 8°C. Six samples were assayed at each time point out to 66 days by a stability-indicating high-performance liquid chromatography method. The method was validated for its specificity through forced degradation studies. The sample remained within 90% to 110% of the initial concentration throughout the course of the study. The beyond-use date of this product is at least 66 days, based on data collected when refrigerated and protected from light.
Related Keywords
- ursodiol
- bile acid
- gallstones
- cholelithiasis
- oral suspension
- stability
Related Categories
- EXCIPIENTS
- GASTROENTEROLOGY
- PEER-REVIEWED
- STABILITIES, COMPATIBILITIES
- DOSAGE FORMS/DRUG CARRIERS
- STORAGE
Related Articles from IJPC
Issue/Page View/Buy |
Title/Author (Click for Abstract / Details / Purchase) |
---|---|
Nov/Dec 2012
Pg. 510-512
|
|
Nov/Dec 2019
Pg. 493
|
Author(s):
Allen Loyd V Jr
|
Jan/Feb 2003
Pg. 48-50
|
Author(s):
Allen Loyd V Jr
|
Jan/Feb 2019
Pg. 70-76
|
|
Sep/Oct 2011
Pg. 427
|
Author(s):
Allen Loyd V Jr
|
Jul/Aug 2013
Pg. 344-346
|
|
Jan/Feb 2010
Pg. 82-85
|
Author(s):
Voudrie Mark A II, Allen D Brett
|
Nov/Dec 2005
Pg. 480
|
Author(s):
Allen Loyd V Jr
|
Jul/Aug 2020
Pg. 327-336
|
|
Jul/Aug 2021
Pg. 327
|
Author(s):
Allen Loyd V Jr
|
Mar/Apr 2022
Pg. 146
|
Author(s):
Allen Loyd V Jr
|
Sep/Oct 2015
Pg. 420-427
|
|
May/Jun 2020
Pg. 232
|
Author(s):
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 54
|
Author(s):
Allen Loyd V Jr
|
Jul/Aug 2012
Pg. 347-349
|
|
Sep/Oct 2003
Pg. 382
|
Author(s):
Allen Loyd V Jr
|
Nov/Dec 2008
Pg. 558-564
|
|
Mar/Apr 1997
Pg. 90-92
|
Author(s):
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 321
|
Author(s):
Allen Loyd V Jr
|
Mar/Apr 2016
Pg. 159-163
|